Lepu Biopharma Co (HKSE:02157) PE Ratio: 23.86 (As of Sep. 15, 2026) — 14% Below Median

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

HKSE:02157 Lepu Biopharma Co Ltd HKSE:02157
44 GF Score
Price HK$3.99
GF Value HK$16.99
Valuation Possible Value Trap
! 6 Warning Signs
View Full Analysis

What is Lepu Biopharma Co PE Ratio?

Lepu Biopharma Co HKSE:02157 44 PE Ratio is 23.86 as of Sep. 15, 2026, which is 14% below its 10-year median of 27.59. GuruFocus rates HKSE:02157 with a GF Score™ of 44/100 and a GF Value™ of HK$16.99 (Possible Value Trap). The stock has 6 warning signs investors should review.

The PE Ratio, or Price-to-Earnings ratio, or P/E Ratio, is a financial ratio used to compare a company's market price to its Earnings per Share (Diluted). As of today (2026-09-15), Lepu Biopharma Co's share price is HK$3.985. Lepu Biopharma Co's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2025 was HK$0.17. Therefore, Lepu Biopharma Co's PE Ratio for today is 23.86.

Good Sign:

Lepu Biopharma Co Ltd stock PE Ratio (=22.5) is close to 1-year low of 21.57.

During the past 7 years, Lepu Biopharma Co's highest PE Ratio was 38.37. The lowest was 21.57. And the median was 27.59.

Lepu Biopharma Co's EPS (Diluted) for the six months ended in Dec. 2025 was HK$0.14. Its EPS (Diluted) for the trailing twelve months (TTM) ended in Dec. 2025 was HK$0.17.

As of today (2026-09-15), Lepu Biopharma Co's share price is HK$3.985. Lepu Biopharma Co's EPS without NRI for the trailing twelve months (TTM) ended in Dec. 2025 was HK$-0.01. Therefore, Lepu Biopharma Co's PE Ratio without NRI ratio for today is At Loss.

Lepu Biopharma Co's EPS without NRI for the six months ended in Dec. 2025 was HK$-0.03. Its EPS without NRI for the trailing twelve months (TTM) ended in Dec. 2025 was HK$-0.01.

During the past 3 years, the average EPS without NRI Growth Rate was 67.60% per year. During the past 5 years, the average EPS without NRI Growth Rate was 44.50% per year.

During the past 7 years, Lepu Biopharma Co's highest 3-Year average EPS without NRI Growth Rate was 67.60% per year. The lowest was -16.10% per year. And the median was 29.00% per year.

Lepu Biopharma Co's EPS (Basic) for the six months ended in Dec. 2025 was HK$0.14. Its EPS (Basic) for the trailing twelve months (TTM) ended in Dec. 2025 was HK$0.17.

Back to Basics: PE Ratio


Lepu Biopharma Co  (HKSE:02157) PE Ratio Explanation

The PE Ratio can be viewed as the number of years it takes for the company to earn back the price you pay for the stock. For example, if a company earns $2 a share per year, and the stock is traded at $30, the PE Ratio is 15. Therefore it takes 15 years for the company to earn back the $30 you paid for its stock, assuming the earnings stays constant over the next 15 years.

In real business, earnings never stay constant. If a company can grow its earnings, it takes fewer years for the company to earn back the price you pay for the stock. If a company's earnings decline it takes more years. As a shareholder, you want the company to earn back the price you pay as soon as possible. Therefore, lower P/E stocks are more attractive than higher P/E stocks so long as the PE Ratio is positive. Also for stocks with the same PE Ratio, the one with faster growth business is more attractive.

If a company loses money, the PE Ratio becomes meaningless.

To compare stocks with different growth rates, Peter Lynch invented a ratio called PEG Ratio. PEG Ratio is defined as the PE Ratio divided by the growth ratio. He thinks a company with a PE Ratio equal to its growth rate is fairly valued. Still he said he would rather buy a company growing 20% a year with a PE Ratio of 20, instead of a company growing 10% a year with a PE Ratio of 10.

Because the PE Ratio measures how long it takes to earn back the price you pay, the PE Ratio can be applied to the stocks across different industries. That is why it is the one of the most important and widely used indicators for the valuation of stocks.

Similar to the PE Ratio without NRI or PS Ratio or Price-to-Operating-Cash-Flow or Price-to-Free-Cash-Flow , the PE Ratio measures the valuation based on the earning power of the company. This is where it is different from the PB Ratio , which measures the valuation based on the company's balance sheet.


Be Aware

Investors need to be aware that the PE Ratio can be misleading a lot of times, especially when the underlying business is cyclical and unpredictable. As Peter Lynch pointed out, cyclical businesses have higher profit margins at the peaks of the business cycles. Their earnings are high and PE Ratios are artificially low. It is usually a bad idea to buy a cyclical business when the PE Ratio is low. A better ratio to identify the time to buy a cyclical businesses is the PS Ratio.

PE Ratio can also be affected by non-recurring-items such as the sale of part of businesses. This may increase for the current year or quarter dramatically. But it cannot be repeated over and over. Therefore PE Ratio without NRI is a more accurate indication of valuation than PE Ratio.


Lepu Biopharma Co PE Ratio Related Terms


Lepu Biopharma Co PE Ratio Historical Data

* Premium members only.

The historical data trend for Lepu Biopharma Co's PE Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Lepu Biopharma Co PE Ratio Chart

Lepu Biopharma Co Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
PE Ratio
Get a 7-Day Free Trial N/A At Loss At Loss At Loss 30.12

Lepu Biopharma Co Semi-Annual Data
Dec19 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25 Jun26
PE Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only At Loss At Loss At Loss 30.12 At Loss

HKSE:02157 vs VRTX, REGN, MRNA: PE Ratio Comparison

For the Biotechnology subindustry, Lepu Biopharma Co's PE Ratio, along with its competitors' market caps and PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Lepu Biopharma Co PE Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Lepu Biopharma Co's PE Ratio distribution charts can be found below:

* The bar in red indicates where Lepu Biopharma Co's PE Ratio falls into.


HKSE:02157
44GF Score
Lepu Biopharma Co Ltd HKSE:02157
PE Ratio is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Lepu Biopharma Co PE Ratio Calculation

The PE Ratio, or Price-to-Earnings ratio, or P/E Ratio, is a financial ratio used to compare a company's market price to its Earnings per Share (Diluted). It is the most widely used ratio in the valuation of stocks.

Lepu Biopharma Co's PE Ratio for today is calculated as

PE Ratio=Share Price/Earnings per Share (Diluted) (TTM)
=3.985/0.167
=23.86

Lepu Biopharma Co's Share Price of today is HK$3.985.
For company reported semi-annually, Lepu Biopharma Co's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was HK$0.17.


* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

It can also be calculated from the numbers for the whole company:


There are at least three kinds of PE Ratios used by different investors. They are Trailing Twelve Month PE Ratio, Forward PE Ratio, or PE Ratio without NRI. A new PE Ratio based on inflation-adjusted normalized PE Ratio is called Shiller PE Ratio, after Yale professor Robert Shiller.

In the calculation of PE Ratio, the earnings per share used are the earnings per share over the past 12 months. For Forward PE Ratio, the earnings are the expected earnings for the next twelve months. In the case of PE Ratio without NRI, the reported earnings less the non-recurring items are used.

For Shiller PE Ratio, the earnings of the past 10 years are inflation-adjusted and averaged. Since it looks at the average over the last 10 years, Shiller PE Ratio is also called PE10.

Frequently Asked Questions Learn more about PE Ratio →
What does a PE Ratio of 23.86 mean?
Lepu Biopharma Co (HKSE:02157) has a PE Ratio of 23.86 as of Sep. 15, 2026. P/E ratio is the ratio of share price to a company's earnings per share. View historical data on Lepu Biopharma Co and its competitors. This is 14% below median its historical median of 27.59. Over the past decade, Lepu Biopharma Co's PE Ratio has ranged from 21.57 to 38.37.
Is Lepu Biopharma Co's PE Ratio too high?
Lepu Biopharma Co's current PE Ratio of 23.86 is 14% below median its 10-year median of 27.59. Over the past 10 years, this metric has ranged from a low of 21.57 to a high of 38.37. Overall, Lepu Biopharma Co has a GF Score™ of 44/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Lepu Biopharma Co's PE Ratio compare to VRTX and REGN?
Lepu Biopharma Co's PE Ratio of 23.86 can be compared against companies in the Biotechnology industry. Historically, Lepu Biopharma Co's own PE Ratio has ranged from 21.57 to 38.37 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PE Ratio for a Biotechnology company?
A good PE Ratio depends on the Biotechnology industry context. However, PE Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PE Ratio mean?
A high PE Ratio can signal that a stock is expensive relative to its fundamentals. P/E ratio is the ratio of share price to a company's earnings per share. View historical data on Lepu Biopharma Co and its competitors. Lepu Biopharma Co's current PE Ratio is 23.86, which is 14% below median its own 10-year median of 27.59. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Lepu Biopharma Co stock overvalued right now?
Based on GuruFocus' analysis, Lepu Biopharma Co (HKSE:02157) is currently considered Possible Value Trap. The stock's GF Value™ is HK$16.99, compared to a current price of HK$3.99 — trading 76.5% below its estimated fair value. The current PE Ratio is 23.86, which is 14% below median its 10-year median of 27.59. Lepu Biopharma Co's overall GF Score™ is 44/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PE Ratio calculated?
PE Ratio is calculated from a company's financial statements. For Lepu Biopharma Co (HKSE:02157), the current PE Ratio is 23.86 as of Sep. 15, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Lepu Biopharma Co (HKSE:02157) Overvalued in 2026?

Based on GuruFocus' analysis, Lepu Biopharma Co stock appears to be undervalued. The current stock price of HK$3.99 is trading 76.5% below its estimated GF Value™ of HK$16.99. GuruFocus considers Lepu Biopharma Co to be Possible Value Trap.

Key valuation signals for HKSE:02157:

  • PE Ratio: 23.86 (14% below median its 10-year median of 27.59)
  • GF Value™: HK$16.99 vs. price of HK$3.99 (76.5% below fair value)
  • GF Score™: 44/100 with 6 warning signs

No single metric tells the full story. See the HKSE:02157 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Lepu Biopharma Co Business Description

Address Lianheng Road, Block 4, No. 651, Minhang District, Shanghai, CHN, 201112
Lepu Biopharma Co Ltd is focused on discovering, developing, and commercializing drug candidates in anti-tumor targeted therapy and oncology immunotherapy. Its commercial products include Puyouheng (Pucotenlimab Injection) and Meiyouheng (Becotatug Vedotin Injection). In addition, two other products, CMG901 and MRG007, have also been licensed out through its business development activities. Additionally, the company has several clinical-stage drug candidates and clinical-stage combination therapies of candidates, which are being developed as targeted therapeutics and immunotherapeutics. The various drug candidates in its pipeline include MRG003, MRG002, MRG004A, CG0070, MRG001, and MRG006A, among others. Geographically, the company generates maximum revenue from the Chinese mainland.
44GF Score

Get the complete analysis for HKSE:02157

PE Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

HK$3.99
Price
HK$16.99
GF Value